Showing results (291-300 of 933) with videos related to

Sort By:
Pageof 94
Ejhaem|December 22, 2025
Validation of an Adapted NGS-Based Clonality Assay for MRD Monitoring in B-ALL Using Archived and Follow-Up SamplesMoushumi Suryavanshi, Prashant Mehta, Nitin Jain, et al.
American Journal of Hematology|February 27, 2026
The Care and Cure of the Leukemias in 2026Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Cancer|June 19, 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trialNitin Jain, James M Reuben, Hagop Kantarjian, et al.
Blood|September 27, 2008
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Cancer|December 20, 2002
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemiaMarco Montillo, Alessandra Tedeschi, Susan O'Brien, et al.
Blood|May 22, 2008
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaConstantine S Tam, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|October 1, 2005
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylateElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 94